Anzeige
Mehr »
Login
Mittwoch, 25.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFQB | ISIN: US9840156023 | Ticker-Symbol: 3XB0
NASDAQ
24.12.24
15:30 Uhr
4,180 US-Dollar
-0,110
-2,56 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XENETIC BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
XENETIC BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur XENETIC BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.12.Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment162Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement...
► Artikel lesen
16.12.Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform152Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc....
► Artikel lesen
13.12.Xenetic Biosciences, Inc. - 8-K, Current Report-
05.12.Xenetic und PeriNess kooperieren bei Krebsbehandlungsstudien1
XENETIC BIOSCIENCES Aktie jetzt für 0€ handeln
05.12.Xenetic and PeriNess partner for cancer treatment trials3
05.12.Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program258Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA /...
► Artikel lesen
22.11.Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment198Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC)...
► Artikel lesen
21.11.Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis159Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase...
► Artikel lesen
13.11.Xenetic Biosciences GAAP EPS of -$0.28, revenue of $614.1M2
13.11.Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results177Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for...
► Artikel lesen
13.11.Xenetic Biosciences, Inc. - 8-K, Current Report1
12.11.Xenetic Biosciences, Inc. - 10-Q, Quarterly Report-
12.11.Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models204Data presented at Society for Immunotherapy of Cancer (SITC) 2024Systemic DNase I combined with ??-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against...
► Artikel lesen
07.11.Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform168Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO)...
► Artikel lesen
31.10.Xenetic Biosciences gibt Änderungen im Vorstand bekannt2
31.10.Xenetic Biosciences announces board member changes1
31.10.Xenetic Biosciences, Inc. - 8-K, Current Report1
22.10.Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer 2024200FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies...
► Artikel lesen
21.10.Xenetic Biosciences files for $50M mixed securities shelf1
17.10.Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform226Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic...
► Artikel lesen
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1